Pemfexy Injection
Product Images NDC 42367-531

11 FDA label images from Eagle Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Pemfexy (NDC 42367-531). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eagle Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Pemfexy Figure 01)

Chemical Structure (Pemfexy Figure 01)
Chemical structure of pemetrexed, the active ingredient in Pemfexy injection. The structure shows the molecular arrangement including amine, carboxyl, and aromatic groups characteristic of pemetrexed.*
FDA Label Image

Figure 1 (Pemfexy Figure 02)

Figure 1 (Pemfexy Figure 02)
A survival probability curve graph comparing Pemfexy plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) over a survival time of up to 30 months. The x-axis represents survival time in months, and the y-axis shows survival probability from 0 to 1. Patient risk numbers at various time points are listed below the graph for both PC and GC groups.*
FDA Label Image

Figure 2 (Pemfexy Figure 03)

Figure 2 (Pemfexy Figure 03)
A survival probability Kaplan-Meier curve comparing Pemfexy + Cisplatin (PC) and Gemcitabine + Cisplatin (GC) over a survival time of up to 30 months. The solid line represents PC treatment, and the dotted line represents GC treatment. Patient numbers at risk for both treatments are listed below the graph at various time points.*
FDA Label Image

Figure 3 (Pemfexy Figure 04)

Figure 3 (Pemfexy Figure 04)
A Kaplan-Meier survival curve showing survival probability over time (months) for two treatment groups: Pemfexy (pemetrexed) plus Cisplatin (AC) and Gemcitabine plus Cisplatin (GC). The chart includes patient numbers at risk at various time points for both groups, illustrating survival trends up to 30 months.*
FDA Label Image

Figure 4 (Pemfexy Figure 05)

Figure 4 (Pemfexy Figure 05)
A survival curve graph comparing Pemfexy (pemetrexed) injection and placebo over time in months. The y-axis shows survival probability from 0 to 1.0, and the x-axis shows survival time up to 42 months. A solid line represents Pemfexy, and a dotted line represents placebo, with a table below listing patients at risk at various time points for both groups.*
FDA Label Image

Figure 5 (Pemfexy Figure 06)

Figure 5 (Pemfexy Figure 06)
A survival probability graph comparing Pemfexy injection at 25 mg/mL versus placebo over a survival time of up to 42 months. The graph shows survival probability on the y-axis and time in months on the x-axis, with Pemfexy data represented by a solid line and placebo by a dotted line. A table below indicates the number of patients at risk for each group at various time points.*
FDA Label Image

Figure 6 (Pemfexy Figure 07)

Figure 6 (Pemfexy Figure 07)
A survival curve graph comparing Pemfexy injection versus placebo, showing survival probability over survival time in months. The chart includes two lines representing Pemfexy and placebo, with patient numbers at risk listed below for both groups at various time points.*
FDA Label Image

Figure 7 (Pemfexy Figure 08)

Figure 7 (Pemfexy Figure 08)
A Kaplan-Meier survival curve comparing survival probability over time (months) for Pemfexy injection versus placebo. The solid line represents Pemfexy and the dotted line represents placebo, showing higher survival probabilities with Pemfexy. A table below shows the number of patients at risk for each group at different time points up to 36 months.*
FDA Label Image

Figure 8 (Pemfexy Figure 09)

Figure 8 (Pemfexy Figure 09)
A survival probability Kaplan-Meier plot comparing Pemfexy plus Cisplatin versus Cisplatin alone over survival time in months. The graph includes a table showing the number of patients at risk at various time points for each treatment group. The X-axis represents survival time in months, and the Y-axis represents survival probability.*
FDA Label Image

25mg/ml Vial Label (Pemfexy Figure 10)

25mg/ml Vial Label (Pemfexy Figure 10)
Label for Pemfexy (pemetrexed injection) 500 mg/20 mL (25 mg/mL) multi-dose vial by Eagle Pharmaceuticals, Inc. The sterile intravenous injection is noted as a cytotoxic agent with instructions for dilution before intravenous infusion. Label includes storage conditions, handling cautions, and a discard after date section.*
FDA Label Image

25mg/ml Vial Label (Pemfexy Figure 11)

25mg/ml Vial Label (Pemfexy Figure 11)
Packaging label for Pemfexy (pemetrexed injection) 25 mg/mL, 500 mg/20 mL multi-dose vial by Eagle Pharmaceuticals, Inc. The label states it is for intravenous infusion after dilution and contains cautions about cytotoxicity. It includes storage information and barcode details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.